Related Experiment Videos
Interstitial lung disease points to consider for clinical trials in systemic sclerosis
Dinesh Khanna1, James Seibold2, Jonathan Goldin3
1Department of Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI.
Rheumatology (Oxford, England)
|October 10, 2017
Abstract:
Interstitial lung disease causes major morbidity and mortality in patients with systemic sclerosis (SSc-ILD). Large randomized clinical trials in SSc-ILD have provided important information regarding the feasibility, reliability and validity of outcome measures. Forced vital capacity percentage predicted should be considered as a primary outcome measure, with inclusion of appropriate radiological and patient-reported measures. We provide practical recommendations for trial design in SSc-ILD.